The global growth of the transfection reagent market can be attributed to factors such as advancements in transfection technology, global alliances among leading research institutes to trigger drug discovery, increase in R&D spending and research activities by pharmaceutical and biotechnology companies, increase in demand for synthetic genes, and rising incidence of cancer.
Moreover, development of large scale transfections, rising demand of protein therapeutics, and emerging markets across India and China are likely to create opportunities for players operating in the market.
The global transfection reagent market includes forecast from 2016 to 2021. This market is expected to reach USD 1.02 Billion by 2021 from USD 715.4 Million in 2016, at a CAGR of 7.5% during the forecast period.
The global transfection equipment market is segmented on the basis of product, method, application, end user, and region. Based on product, the market is segmented into reagents and instruments. In 2016, the reagents segment is estimated to account for the largest share of the market. However, the instruments segment is expected to grow at the highest CAGR during the forecast period.
Download PDF Brochure@
The overall market was dominated by Thermo Fisher Scientific Inc. (U.S.), Promega Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), and QIAGEN N.V. (Netherlands). Other players include Polyplus-transfection SA (France), Bio-Rad Laboratories Inc. (U.S.), Lonza Group (Switzerland), Sigma-Aldrich Corporation (U.S.), Mirus Bio LLC (U.S.), and MaxCyte, Inc. (U.S.).
Growth Strategies Adopted by Them:
The key players in this market are continuously striving to gain larger shares and expand their existing product portfolios by agreements, collaborations, and partnerships.
Thermo Fisher Scientific Inc. (U.S.) is leading player in the transfection reagents and equipment market with a market share of ~61.5% in 2015. The company primarily focuses on growth strategies such as acquisitions to add innovative technologies and products to its portfolio, which in turn helps the company to strengthen its presence in the respective markets.
Thermo Fisher acquired Affymetrix, Inc. (U.S.) in 2016, Advanced Scientifics, Inc. (U.S.) in 2015, and Life Technologies Corporation (U.S.) in 2014. This helped the company to expand its customer base and significantly boost its market share. The company’s major share in the transfection reagents and equipment market can be attributed to its broad product portfolio, years of experience, and extensive distribution channel.
# Biopharmaceutical companies
# Biotechnology companies
# Transfection equipment, reagent, and kit manufacturing companies
# Suppliers and distributors of transfection reagents
# Research institutes
# Academic centers
# Venture capitalists
Promega Corporation (U.S.) is another dominant player in the transfection reagents and equipment market. The company accounted for approximately ~17.4% of the market revenue generation. The firm offers more than 3000 products for life science research, particularly in genomics, protein analysis and expression, cellular analysis, drug discovery, and genetic identity. It offers various transfection reagents under its reporter assays and transfection category of products.
Promega has branches in 16 countries with more than 50 global distributors. The company possesses a strong intellectual property portfolio, which helps it to maintain its position in the life science market. Promega owns more than hundred patents in the field of nucleic acid purification, human identification, bioluminescence, coupled in vitro transcription and translation, and cell biology. The company focuses on the strategy of new product development and expansion to strengthen its position in the market.
Request Sample Pages@
Players operating in the transfection reagents and equipment market adopted strategies such as agreements, collaborations, and partnerships to strengthen their global presence.
The key players that have adopted these strategies include MaxCyte, Inc. (U.S.), Polyplus-transfection SA (France), QIAGEN N.V. (Netherlands), Lonza Group Ltd. (Switzerland), F. Hoffmann-La Roche ltd (Switzerland), and Thermo Fisher Scientific Inc. (U.S.)